CRC Shorts Rise, But Peers Face Heavier Pressure

Among California Resources Corporation's closest energy peers, short positioning looks considerably more aggressive at several names. CRC carries 5.2% of its free float sold short, a meaningful but not extreme level compared to the sector sell-off gripping peers right now. APA fell 7.6% on Monday and is down 5.5% on the week. AMPY dropped more than 10% in a single session, off 13.7% across five days. MTDR shed 8.4% on the day. CRC's own 5.2% short interest is therefore not the standout figure in this peer group; what changed recently is the pace at which that short position has been built.

CRC's short interest has climbed 22.6% over the past month, adding roughly 750,000 shares net. The pace picked up sharply in the week to October 30, when positions rose 6.5% in five sessions. That accumulation coincides with the stock falling 5.3% on Monday to $52.54, a single-day move that matched the broader energy rout rather than reflected anything company-specific. The borrow market remains extremely loose: availability runs at 2,280%, meaning there are more than twenty-two times as many shares available to lend as there are currently borrowed. Cost to borrow is 0.49%, low by any measure, though it has risen 76% in a week from a low base. Neither metric points to squeeze dynamics or unusual conviction on the short side.

The activist register adds a layer worth noting. Canada Pension Plan Investment Board filed a Schedule 13D in March 2026, disclosing a 7.9% stake. Constantin von Wasserschleben filed a 13D/A in June 2025, disclosing 4.7%. Schedule 13D filings indicate active rather than passive intent, which places two investors totalling roughly 12.6% of the class on the activist register. Stakes are as last disclosed around the 5% threshold, and a holder can fall below 5% without a further filing. Insider activity over the past 90 days has been one-directional: net sales of approximately 35,700 shares worth just under $1.9 million, led by the EVP and Chief Commercial Officer selling in four identical tranches under a pre-arranged 10b5-1 plan. Planned sales carry less signal weight than discretionary ones, and no open-market buying from senior executives has appeared in the filing record.

Analysts have been nudging targets lower without abandoning positive ratings. UBS trimmed to $68 in mid-October from $73, keeping Buy. Barclays lowered to $74 post-August results, retaining Overweight. The mean target across the coverage group is around $75, implying roughly 43% upside from current levels at $52.54, a gap wide enough to reflect persistent pessimism on near-term oil prices rather than a bullish forecast. EPS surprise ranks in the 94th percentile of ORTEX's universe, and the forward earnings trend score also ranks solidly, but the EV/EBIT factor sits in the 2nd percentile, a valuation flag the bears lean on. The one number that would change the short-interest picture is any sustained break above where the month's accumulation began; the level to watch is closer to $58 to $60, the range at which the October short build started in earnest. The print will test whether CRC's California-focused oil production can deliver a cash-flow quarter that closes that analyst-target gap, or whether the month-long increase in short positioning proves well-timed.